Application of minocycline hydrochloride to preparation of medicine for treating autoimmune uveitis and treatment method of autoimmune uveitis

A minocycline hydrochloride, autoimmune technology, used in drug combinations, active ingredients of tetracycline, allergic diseases, etc. The effect of reducing immune cell infiltration

Inactive Publication Date: 2020-11-03
WENZHOU MEDICAL UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Immunosuppressants and anti-inflammatory drugs are currently the first-line drugs for the clinical treatment of uveitis, but there are disadvantages such as large drug side effects and narrow treatment window

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of minocycline hydrochloride to preparation of medicine for treating autoimmune uveitis and treatment method of autoimmune uveitis
  • Application of minocycline hydrochloride to preparation of medicine for treating autoimmune uveitis and treatment method of autoimmune uveitis
  • Application of minocycline hydrochloride to preparation of medicine for treating autoimmune uveitis and treatment method of autoimmune uveitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Treatment effect of minocycline hydrochloride (MINO) treatment group on autoimmune uveitis (EAU)

[0026] Lewis rats (180-200g) were randomly divided into three groups after injection of 0.1mL IRBP / Freund's adjuvant into the rear foot pad: (1) EAU group; (2) 25 mg / kg MINO group; (3) 50 mg / kg MINO group. Normal Lewis rats served as the control group (Control). On the day of immunization (d0), MINO solution (25 mg / kg and 50 mg / kg) was intraperitoneally injected daily for 14 consecutive days (d14). On the second day after immunization (d2), the inflammatory response of the anterior chamber was observed and scored with a slit lamp. On the 14th day, the rats were sacrificed, the eyeball tissues were taken, and histopathological sections were made to observe the microstructural changes of the retina and score (see attached figure 1 shown).

Embodiment 2

[0028] Minocycline hydrochloride (MINO) treatment group inhibited microglial activation

[0029] On the 14th day, the rats were sacrificed to take eyeball tissues, frozen sections, immunofluorescence staining for IBA-1 and CD68, and observing the activation of microglial cells (see attached figure 2 shown).

Embodiment 3

[0031] Minocycline hydrochloride (MINO) treatment group inhibited the secretion of inflammatory factors in microglial cells

[0032] On the 14th day, the rats were sacrificed to take eyeball tissues, frozen sections, immunofluorescent staining of IBA-1 and IL-1β, and the activation of microglial cells were observed (see appendix image 3 shown).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of minocycline hydrochloride to preparation of a medicine for treating autoimmune uveitis and a treatment method of the autoimmune uveitis. The inventor finds that the minocycline hydrochloride can be used as an early intervention medicine by exploring the treatment effect of minocycline with different administration dosages on the autoimmune uveitis. By inhibiting microglial cell activation of retina tissue, reducing immune cell infiltration and reconstructing a steady state in gastrointestinal tract flora, generation and development of the uveitis are effectively inhibited, a new application is provided for application of the minocycline hydrochloride, and besides, a new strategy and method are provided for early prevention and intervention of the autoimmune uveitis.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to the application of minocycline hydrochloride as a medicine for the preparation of autoimmune uveitis and its treatment method. Background technique [0002] Uveitis is a class of various diseases with complex etiology. Although infection, trauma and other factors can cause uveitis, it is generally believed that uveitis caused by autoimmune disorders is the most common and important type. The main mechanism of autoimmune reactive uveitis is the imbalance of effector type Ⅰ helper T cells (helper T lymphocyte 1, Th1) and Th17, regulatory T cells (regulatory T cells, Tr) population. Immunosuppressants and anti-inflammatory drugs are currently the first-line drugs for the clinical treatment of uveitis, but they have disadvantages such as large toxic side effects and narrow treatment window. Contents of the invention [0003] In order to overcome the defects of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/65A61P27/02A61P37/02A61P1/00
CPCA61K31/65A61P27/02A61P37/02A61P1/00
Inventor 李星熠王毓琴周建宏陈浩
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap